Cargando…
Isothiocyanates (ITCs) 1-(Isothiocyanatomethyl)-4-phenylbenzene and 1-Isothiocyanato-3,5-bis(trifluoromethyl)benzene—Aldehyde Dehydrogenase (ALDH) Inhibitors, Decreases Cisplatin Tolerance and Migratory Ability of NSCLC
One of the main treatment modalities for non-small-cell lung cancer (NSCLC) is cisplatin-based chemotherapy. However, the acquisition of cisplatin resistance remains a major problem. Existing chemotherapy regimens are often ineffective against cancer cells expressing aldehyde dehydrogenase (ALDH). A...
Autores principales: | Kryczka, Jolanta, Kryczka, Jakub, Janczewski, Łukasz, Gajda, Anna, Frączyk, Andrzej, Boncela, Joanna, Kolesińska, Beata, Brzeziańska-Lasota, Ewa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369118/ https://www.ncbi.nlm.nih.gov/pubmed/35955773 http://dx.doi.org/10.3390/ijms23158644 |
Ejemplares similares
-
The Comparison of Serum Exosome Protein Profile in Diagnosis of NSCLC Patients
por: Baran, Kamila, et al.
Publicado: (2023) -
Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy
por: Kryczka, Jolanta, et al.
Publicado: (2021) -
Leukocytes: The Double-Edged Sword in Fibrosis
por: Kryczka, Jakub, et al.
Publicado: (2015) -
Cell Migration Related to MDR—Another Impediment to Effective Chemotherapy?
por: Kryczka, Jakub, et al.
Publicado: (2018) -
Proteases Revisited: Roles and Therapeutic Implications in Fibrosis
por: Kryczka, Jakub, et al.
Publicado: (2017)